Patent SG-11201909048T-A (SG)
Title: Use of klk5 antagonists for treatment of a disease
Inventor: DRESSEN AMY
IPC: C07K14/81
Filed: 2018-04-20
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIP0 I PCT onion °nolo mu ioo Ho oimIE (10) International Publication Number WO 2018/195472 Al (51) International Patent Classification: A61K 38/00 (2006.01) C07K 14/81 (2006.01) (21) International Application Number: PCT/US2018/028637 (22) International Filing Date: 20 April 2018 (20.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/488,515 21 April 2017 (21.04.2017) US (71) Applicant (for all designated States except AL, AT, BA, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR): GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, Califor- nia 94080 (US). (71) Applicant (for AL, AT, BA, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR only): F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, 4070 BASEL (CH). (72) Inventors: DRESSEN, Amy; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). IAEA, David B.; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). ISMAILI, Moulay Hicham Alaoui; 128 Seville Way, San Mateo, California 94402 (US). JACKMAN, Janet K.; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). LAZARUS, Robert A.; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). LOYET, Kel- ly; c/o Genentech, Inc., 1 DNA Way, South San Francis- co, California 94080 (US). MAUN, Henry R.; Grenzach- erstrasse 124, 4070 Basel (CH). YASPAN, Brian L.; c/o Genentech, Inc., 1 DNA Way, South San Francisco, Cali- fornia 94080 (US). YI, Tangsheng; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). ARRON, Joseph R.; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). HERNAN- DEZ-BARRY, Hilda Y.; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) W O 20 18/ 195 47 2 Al (74) Agent: BERENDT, Frank JN et al.; c/o Genentech, Inc., 1 DNA Way, South San Francisco, California 94080 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (54) Title: USE OF KLK5 ANTAGONISTS FOR TREATMENT OF A DISEASE (57) : Provided herein are methods of treating a subject, methods of predicting the response of a subject and selecting a subject suffering from a disease associated with KLK5, such as asthma or Netherton Syndrome. In particular, provided herein are uses of KLK5 antagonists for the treatment or diagnosis of asthma or Netherton Syndrome, such as an antibody or an Fc fusion polypeptide as well as pharmaceutical formulations comprising the same.